Cellectis, the rational genome engineering company, and Celonic GmbH, announced today that they entered into a collaboration agreement under which Celonic will develop with the Meganuclease Recombination System (MRS) technology of Cellectis, new generation of I-SceI meganuclease tagged host cell lines for biopharmaceuticals production.
